Literature DB >> 16642400

The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential.

Tammy A Castro1, Marion C Cohen, Pranela Rameshwar.   

Abstract

Breast cancer has a predilection for metastasis to the bone marrow. The preprotachykinin-I (PPT-I) gene has a central role in the early migration of breast cancer cells into the bone marrow, making this organ a latent repository of the cancer cells. This study investigated whether the invasive and metastatic potential of breast cancer cells correlate with the expression of the PPT-I gene and the receptors for its peptides, neurokinin-1 (NK-1) and NK-2. The studies compared cells that are non-tumorigenic (MCF12A), low metastatic and invasive potential (MCF7), and sublines of MCF with increased invasive and metastatic potential (LCC1 and LCC2). LCC2, but not LCC1 is tamoxifen resistant. Quantitative RT-PCR showed increased expression of PPT-I, NK-1 and NK-2 mRNA LCC1 and LCC2. MCF7 required stimulation by phorbol ester for NK-1 induction. The levels of NK-2 mRNA were significantly increased in LCC2. Clonogenic assays with specific receptor antagonists showed a predominant role for NK-2 in the proliferation of both LCC1 and LCC2. While the growth rate of LCC1 and LCC2 were similar, the latter showed increased migration. Use of a nude mouse model confirmed higher metastatic potential of LCC2, including increased migration to regions of the endosteum. Overall, these studies show a correlation between three neuroendocrine-related genes: PPT-I, NK-1 and NK-2 and the metastatic potential of specific breast cancer cells. These cells provide a model for future studies on bone marrow metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16642400     DOI: 10.1007/s10585-006-9001-6

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

1.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.

Authors:  S Braun; K Pantel; P Müller; W Janni; F Hepp; C R Kentenich; S Gastroph; A Wischnik; T Dimpfl; G Kindermann; G Riethmüller; G Schlimok
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

2.  Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5'-monophosphate response elements in its expression by IL-1 and stem cell factor.

Authors:  J Qian; G Yehia; C Molina; A Fernandes; R Donnelly; D Anjaria; P Gascon; P Rameshwar
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

3.  Human monocytes and macrophages express substance P and neurokinin-1 receptor.

Authors:  W Z Ho; J P Lai; X H Zhu; M Uvaydova; S D Douglas
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

4.  Protein kinase C-mediated desensitization of the neurokinin 1 receptor.

Authors:  O Déry; K A Defea; N W Bunnett
Journal:  Am J Physiol Cell Physiol       Date:  2001-05       Impact factor: 4.249

5.  Chemoattraction of neutrophils by substance P and transforming growth factor-beta 1 is inadequately explained by current models of lipid remodeling.

Authors:  K A Haines; S L Kolasinski; B N Cronstein; J Reibman; L I Gold; G Weissmann
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

6.  Differences in the expression of neurokinin receptor in neural and bone marrow mesenchymal cells: implications for neuronal expansion from bone marrow cells.

Authors:  P S Bandari; J Qian; G Yehia; H P Seegopaul; J S Harrison; P Gascon; H Fernandes; P Rameshwar
Journal:  Neuropeptides       Date:  2002-02       Impact factor: 3.286

7.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Authors:  R Clarke; N Brünner; B S Katzenellenbogen; E W Thompson; M J Norman; C Koppi; S Paik; M E Lippman; R B Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.

Authors:  E W Thompson; S Paik; N Brünner; C L Sommers; G Zugmaier; R Clarke; T B Shima; J Torri; S Donahue; M E Lippman
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

9.  Crosstalk between neurokinin receptors is relevant to hematopoietic regulation: cloning and characterization of neurokinin-2 promoter.

Authors:  Persis S Bandari; Jing Qian; Hyun S Oh; Julius A Potian; Ghassan Yehia; Jonathan S Harrison; Pranela Rameshwar
Journal:  J Neuroimmunol       Date:  2003-05       Impact factor: 3.478

10.  cDNA sequence of human beta-preprotachykinin, the common precursor to substance P and neurokinin A.

Authors:  A J Harmar; A Armstrong; J C Pascall; K Chapman; R Rosie; A Curtis; J Going; C R Edwards; G Fink
Journal:  FEBS Lett       Date:  1986-11-10       Impact factor: 4.124

View more
  5 in total

1.  Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage.

Authors:  Agnès Garnier; Matthias Ilmer; Kristina Becker; Beate Häberle; Dietrich VON Schweinitz; Roland Kappler; Michael Berger
Journal:  Oncol Lett       Date:  2015-11-20       Impact factor: 2.967

Review 2.  The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Authors:  Marisa Rosso; Miguel Muñoz; Michael Berger
Journal:  ScientificWorldJournal       Date:  2012-04-01

Review 3.  Biological and Pharmacological Aspects of the NK1-Receptor.

Authors:  Susana Garcia-Recio; Pedro Gascón
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

4.  Role of the nervous system in cancer metastasis.

Authors:  Sha Li; Yanlai Sun; Dongwei Gao
Journal:  Oncol Lett       Date:  2013-01-31       Impact factor: 2.967

5.  Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231LUC+).

Authors:  Silvia Gutierrez; M Danilo Boada
Journal:  Cancer Cell Int       Date:  2018-12-22       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.